Veramarx developed the first early stage test for Lyme disease with > 90% accuracy versus current tests with 0% accuracy at the early stage.
Veramarx has developed a multi-analyte, algorithm based diagnostic test for early stage Lyme disease. This is a large, fast growing market where current diagnostic methods are inadequate. The current test has 40% accuracy. Veramarx recently completed a third validation study demonstrating 90% accuracy. Reimbursement, rapid adoption and compelling health economics have been established by gathering input from industry experts and clinicians.